Pherecydes Pharma expands its patent portfolio with a new patent granted in Hong Kong
11 Maggio 2021 - 7:00AM
Business Wire
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 - ALPHE), a
biotechnology company specializing in precision phage therapy to
treat resistant and/or complicated bacterial infections, today
announced that the Hong Kong authorities have granted a patent for
its anti-Pseudomonas Aeruginosa phages in that jurisdiction.
This patent, as well as those already granted in the United
States, Israel, Japan, Europe and Australia, protect Pherecydes
Pharma’s intellectual property through to the end of 2034.
Guy-Charles Fanneau de La Horie, Chairman of the Executive
Board of Pherecydes Pharma, said: “We are very pleased to be
further strengthening our intellectual property. Following the
patents granted in the United States a few weeks ago, the granting
of a patent for our anti-Pseudomonas aeruginosa phages in Hong Kong
is further good news in terms of protection in this domain. This is
part of our continuous efforts to protect the investments we have
made in the past in our winning phages and the aggressive stance we
have adopted in this new therapeutic field that is precision phage
therapy. This patent has thus been granted in a substantial portion
of the largest pharmaceutical markets, giving it great value”.
Pherecydes Pharma has an active portfolio of four patents, each
covering multiple phages and their variants against the target
bacteria: Pseudomonas aeruginosa, Staphylococcus aureus and
Escherichia Coli. While some patents are still pending, others have
already been granted in major jurisdictions such as the United
States, Europe, Japan, Australia, Hong Kong and Israel.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company
that develops treatments against resistant bacterial infections,
responsible for many serious infections. The Company has developed
an innovative approach, precision phage therapy, based on the use
of phages, natural bacteria-killing viruses. Pherecydes Pharma is
developing a portfolio of phages targeting 3 of the most resistant
and dangerous bacteria, which alone account for more than two
thirds of hospital-acquired resistant infections: Staphylococcus
aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of
precision phage therapy has been successfully applied in 26
patients in the context of compassionate use, under the supervision
of the French National Agency for the Safety of Medicines (ANSM).
Headquartered in Nantes, Pherecydes Pharma has a team of around
twenty experts from the pharmaceutical industry, biotechnology
sector and academic research.
For more information, www.pherecydes-pharma.com
Disclaimer
This press release contains non-factual elements, including, but
not limited to, certain statements regarding future results and
other future events. These statements are based on the current
vision and assumptions of the management of the Company. They
incorporate known and unknown risks and uncertainties that could
result in significant differences in results, profitability and
expected events. In addition, Pherecydes Pharma, its shareholders
and its affiliates, directors, officers, counsels and employees
have not verified the accuracy of, and make no representations or
warranties about, statistical information or forecast information
contained within this news release and that originates or is
derived from third party sources or industry publications; these
statistical data and forecast information are only used in this
press release for information purposes. Finally, this press release
may be drafted in French and in English. In the event of
differences between the two texts, the French version will
prevail.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210510006028/en/
Pherecydes Pharma Philippe Rousseau CFO
investors@pherecydes-pharma.com
NewCap Dusan Oresansky Investor Relations
pherecydes@newcap.eu T.: +33 1 44 71 94 92
NewCap Nicolas Merigeau Media Relations pherecydes@newcap.eu T.:
+33 1 44 71 94 98